Clinical Trials Logo

Astrocytoma, Grade III clinical trials

View clinical trials related to Astrocytoma, Grade III.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04757662 Completed - Clinical trials for Astrocytoma, Grade IV

Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma

Start date: May 14, 2021
Phase: Phase 1
Study type: Interventional

Increasing preclinical and clinical data have shown that myeloid-derived suppressor cells (MDSCs) may represent a significant driver of immunosuppression in glioblastoma (GBM, grade IV astrocytoma) and a potential mechanism of treatment resistance to chemoradiotherapy. Tadalafil, an FDA-approved drug with inexpensive cost and excellent safety profile, has been shown to effectively reduce MDSCs and restore T-cell activation in the peripheral blood and in the tumor microenvironment. The purpose of this study is to investigate the impact of targeting MDSCs in newly diagnosed IDH-wildtype grade III-IV astrocytoma by combining tadalafil with standard of care radiation therapy (RT) and temozolomide (TMZ).

NCT ID: NCT03224104 Completed - Glioblastoma Clinical Trials

Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma

STEAM
Start date: June 12, 2018
Phase: Phase 1
Study type: Interventional

This is a three parallel cohort, open-labeled, non-randomized, multicenter study. All three cohorts will enroll independently.

NCT ID: NCT03072134 Completed - Glioma Clinical Trials

Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma

Start date: April 24, 2017
Phase: Phase 1
Study type: Interventional

Malignant gliomas have a very poor prognosis with median survival measured in months rather than years. It is a disease in great need of novel therapeutic approaches. Based on the encouraging results of our preclinical studies which demonstrate improved efficacy without added toxicity, the paradigm of delivering a novel oncolytic adenovirus via a neural stem cell line in combination with radiation and chemotherapy is well-suited for evaluation in newly diagnosed malignant gliomas. The standard-of-care allows application of virotherapy as neoadjuvant therapy and assessment of the cooperative effects with radiation/chemotherapy without altering the standard treatment.

NCT ID: NCT02644291 Completed - Glioblastoma Clinical Trials

Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors

Start date: May 2016
Phase: Phase 1
Study type: Interventional

This is a safety (Phase 1) trial using mebendazole for recurrent pediatric brain cancers that include medulloblastoma and high grade glioma, that are no longing responding to standard therapies. The drug mebendazole is an oral drug in a chewable 500 mg orange flavored tablet. It is already approved to treat parasitic infections. The purpose of this study is to determine the safety and side effects for increasing doses of mebendazole, followed by the treatment of an additional 12 patients at the best tolerated dose.